In retrospective studies, we identified the SFN gene (14.3.3sigma) as a methylation target in aggressive NB [8], [9] and found that quantitative methylation differences in SFN discriminated high-risk stage 4 patients with poor survival from those, at the same stage and in the same risk group, with favorable outcome independently from MYCN amplification, treatment, clinical response, histology and age at diagnosis [10]. Here, MYCN is linked to neuroblastoma.